ClinicalTrials.gg
CompletedNCT03233230Updated Sep 28, 2020Results posted

Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis

A Phase 2 interventional study of M2591 25 mg QD and M2951 75 mg QD in Rheumatoid Arthritis, sponsored by EMD Serono Research & Development Institute, Inc.. Completed at 98 sites in 12 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-09-28.

Sponsored by EMD Serono Research & Development Institute, Inc. (part of Merck KGaA, Darmstadt, Germany) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
390
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 290 studies in Arthritis, Rheumatoid with a site in Poland — 13 open to participants now, 22 under way, 3 of them phase 3. Arthritis, Rheumatoid · Poland.

Enrollment
112th of 284
390 · median 292
Started
2017
with 10 others
Phase 2
141 of 290
6 open now
Registered
229th of 290
by date

Among the 290 studies in Arthritis, Rheumatoid with a site in Poland, this one is the 112th largest by enrollment of the 284 interventional ones that give a count, is one of 11 that started in 2017, is one of 141 in phase 2, and was the 229th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

13 of the 290 studies in Arthritis, Rheumatoid with a site in Poland are open now. Recruiting first, the newest first:

8 more — sign in →

All 13 open studies →

A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 290 studies in Arthritis, Rheumatoid with a site in Poland, or all of them as a file.
02

Study summary

The purpose of this study was to determine the efficacy, dose response, and safety of M52951 in participants with Rheumatoid Arthritis (RA), and to consider a dose to took forward into Phase III development.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
  • American College of Rheumatology
  • High-sensitivity C-reactive protein
  • Bruton's tyrosine kinase
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • In Japan, if a participant is less than (\<) 20 years, the written from the participant's parent or guardian will be required in addition to the participant's written consent.
  • Confirmed diagnosis of RA according to 2010 ACR/EULAR RA classification criteria of at least 6 months duration prior to Screening
  • Persistently active moderate to severe RA at both Screening and Randomization (if significant surgical treatment of a joint has been performed, that joint cannot be counted for entry or enrollment purposes), as defined by: >= 6 swollen joints (of 66 assessed) and >= 6 tender joints (of 68 assessed).
  • An hsCRP >= 5.0 milligram/liter (mg/L) at Screening
  • Treatment for >= 16 weeks with 7.5 to 25 mg/week Methotrexate (MTX) at a stable dose and route of administration (oral or parenteral) for at least 8 weeks prior to dosing with the Medicinal Product (IMP) and maintained throughout the trial
  • For participants entering the trial on MTX doses \< 15 mg/week (\< 10 mg/week in Japan), there must be clear documentation in the medical record that higher doses of MTX were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines.
  • For MRI Sub-study participants, participants must have palpable synovitis of the wrist and/or >= 1 of metacarpophalangeal joints 1 to 5, defined as loss of bony contours with palpable joint effusion and/or swelling, in the MRI-designated hand (that is., the hand being used in MRI assessments).

Exclusion criteria

Exclusion Criteria:

  • ACR functional class IV as defined by the ACR classification of functional status or wheelchair/bedbound
  • Use of oral greater than (>) 10 mg daily prednisone equivalent, or change in dose of corticosteroids within 2 weeks prior to Screening or during Screening
  • Use of injectable corticosteroids (including intra-articular corticosteroids) or intra-articular hyaluronic acid within 4 weeks prior to Screening or during Screening
  • Initiation or change in dose for nonsteroidal anti-inflammatory drugs (NSAIDs) (including low-dose aspirin and cyclooxygenase-2 inhibitors) within 2 weeks prior to dosing with the IMP
  • High potency opioid analgesics are prohibited within 2 weeks prior to Screening and during the trial; other analgesics are allowed (that is, acetaminophen, codeine, hydrocodone*, propoxyphene*, or tramadol), although not within 24 hours of study visits with clinical assessments (*not approved in Japan)
  • Current or prior treatment with any of the following:
  • Biologic Disease-modifying anti-rheumatic drugs (DMARDs) (approved or ), including but not limited to:
  • Tumor necrosis factor (TNF) antagonists or biosimilars of these agents (approved or investigational), or any investigational TNF antagonist
  • Interleukin-6 antagonists
  • Abatacept (CTLA4-Fc)
  • Anakinra* (IL-1 receptor antagonist) (*not approved in Japan)
  • B cell-depleting antibodies (example, rituximab, ocrelizumab*, ofatumumab, obinutuzumab*, ocaratuzumab*, veltuzumab*, or any biosimilars of these agents [approved or investigational]) (*not approved in Japan)
  • Anti-BLyS (B lymphocyte stimulator) agents (example, belimumab, tabalumab*) (*not approved in Japan)
  • Dual BLyS/A proliferation-inducing ligand (APRIL) neutralizing agents (that is, atacicept*, RCT-18*) (*not approved in Japan)
  • Targeted synthetic DMARDs, specifically:
  • Janus kinase inhibitors
  • Other Bruton's tyrosine kinase (BTK) inhibitors
  • Alkylating agents (example, chlorambucil*, cyclophosphamide) (*not approved in Japan).
  • The following restrictions on nonbiologic DMARD must be followed:
  • Auranofin (Ridaura), minocycline, penicillamine, sulfasalazine, cyclosporine, mycophenolate (mycophenolate sodium not approved in Japan), tacrolimus, azathioprine: must have been discontinued for 4 weeks prior to dosing with the IMP
  • Leflunomide (Arava) must have been discontinued 12 weeks prior to dosing with the IMP if no elimination procedure is followed. Alternately, it should have been discontinued with the following elimination procedure at least 4 weeks prior to dosing with the IMP:
  • Cholestyramine at a dosage of 8 gram 3 times a day for at least 24 hours, or activated charcoal at a dosage of 50 gram 4 times a day for at least 24 hours.
  • Injectable Gold (aurothioglucose* or aurothiomalate): must have been discontinued for 8 weeks prior to dosing with the IMP (*not approved in Japan)
  • Anti-malarials (hydroxychloroquine, chloroquine*) will be allowed in this trial. Participants may be taking oral hydroxychloroquine (=\< 400 mg/day) or chloroquine (=\< 250 mg/day), doses must have been stable for at least 12 weeks prior to dosing with the IMP, and will need to be continued at that stable dose for the duration of the trial. If discontinued prior to this trial, they must have been discontinued for 4 weeks prior to dosing with the IMP (*not approved in Japan).
  • For MRI Substudy:
  • Inability to comply with MRI scanning, including to MRI such as known allergy to gadolinium contrast media, claustrophobia (if the site does not have ability to scan extremities only), presence of a pacemaker, cochlear implants, ferromagnetic devices or clips, intracranial vascular clips, insulin pumps, and nerve stimulators.
  • More than 25% of applicable joints of the target hand and wrist having had prior surgery or showing maximum Genant-modified Sharp erosion (3.0) or joint-space narrowing (4.0) scores, based on single posteroanterior radiographs of target hand and wrist read centrally.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
390 participants (actual)

Study arms

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Experimental
    M2951 25 mg QD

    Drug: M2591 25 mg QD

  • Experimental
    M2951 75 mg QD

    Drug: M2951 75 mg QD

  • Experimental
    M2951 50 mg BID

    Drug: M2951 50 mg BID

Interventions

  • Participants received 25 milligrams (mg) of M2951 orally once daily (QD) for 12 weeks.

    Also known as: Evobrutinib

  • Participants received 75 mg of M2951 orally QD for 12 weeks.

    Also known as: Evobrutinib

  • Participants received 50 mg of M2951 orally twice daily (BID) for 12 weeks.

    Also known as: Evobrutinib

  • DrugPlacebo

    Participants received placebo matched to M2951 orally for 12 weeks.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants Who Achieved American College of Rheumatology 20 Percent (%) Response Criteria (ACR20) Assessed Using High-Sensitivity C-reactive Protein (hsCRP) at Week 12

    ACR20 response: a participant has at least 20% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with 20% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI); and 5) acute phase reactant as measured by high-sensitivity C-reactive protein (hsCRP). Percentage of participants with ACR20 response using hsCRP = Number of participants with ACR20 response using hsCRP divided by total modified intent-to-treat (mITT) participants \* 100.

    Time frame: Week 12

Secondary outcomes

  1. Percentage of Participants With Low Disease Activity Score (DAS28 Less Than [<] 3.2) Based on 28 Joint Count-High-Sensitivity C-reactive Protein (DAS28-hsCRP) at Week 12

    Disease Activity Score (DAS) based on a 28 joint count hsCRP consisted of composite numerical score of following variables: tender joint count (TJC28), swollen joint count (SJC28), hsCRP (mg/mL), and participant's global assessment of disease activity. DAS28-hsCRP was calculated using following formula: DAS28-hsCRP equals to (=) 0.56\*square root (sqrt) (TJC28) plus (+) 0.28\*sqrt (SJC28) + 0.36\*natural log(hsCRP+1) + 0.014\* participant's global assessment of disease activity + 0.96. Scores ranged 0-9.4, where lower scores indicated less disease activity. Percentage of participants with low DAS28 \< 3.2 based on DAS28- hsCRP at Week 12 were reported.

    Time frame: Week 12

  2. Percentage of Participants With Remission Disease Activity Score (DAS28 Less Than [<] 2.6) Based on a 28 Joint Count-High-Sensitivity C-reactive Protein (DAS28-hsCRP) at Week 12

    Disease Activity Score (DAS) based on a 28 joint count hsCRP consisted of composite numerical score of following variables: tender joint count (TJC28), swollen joint count (SJC28), hsCRP (mg/mL), and participant's global assessment of disease activity. DAS28-hsCRP was calculated using following formula: DAS28-hsCRP equals to (=) 0.56\*square root (sqrt) (TJC28) plus (+) 0.28\*sqrt (SJC28) + 0.36\*natural log(hsCRP+1) + 0.014\* participant's global assessment of disease activity + 0.96. Scores ranged 0-9.4, where lower scores indicated less disease activity. A DAS28 score less than (\<) 2.6 indicated clinical remission. Percentage of participants with low DAS28 \< 2.6 based on DAS28- hsCRP at Week 12 were reported.

    Time frame: Week 12

  3. Percentage of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50)

    ACR50 response: a participant has at least 50% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with 50% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by Health Assessment Questionnaire - Disability Index \[HAQ-DI\]; and 5) acute phase reactant as measured by High-sensitivity C-reactive protein \[hsCRP\]. Percentage of participants with ACR50 response = Number of participants with ACR50 response divided by total mITT participants \* 100.

    Time frame: Week 12

  4. Percentage of Participants Achieving American College of Rheumatology 70% Response Criteria (ACR70)

    ACR70 response: a participant has at least 70% improvement ACR70 response in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with 70% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by Health Assessment Questionnaire - Disability Index \[HAQ-DI\]; and 5) acute phase reactant as measured by High-sensitivity C-reactive protein \[hsCRP\]. Percentage of participants with ACR70 response = Number of participants with ACR70 response divided by total mITT participants \* 100.

    Time frame: Week 12

  5. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)

    Adverse event (AE) was defined as any untoward medical occurrence in a participant, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inparticipant hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs: events between first dose of study drug that were absent before treatment/that worsened relative to pre-treatment state up to 16 weeks. TEAEs included both serious TEAEs and non-serious TEAEs. Number of participants with TEAEs and serious TEAEs were reported.

    Time frame: up to Week 16

  6. Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)

    Severity of TEAEs were graded using NCI-CTCAE v4.03 toxicity grades, as follows: Grade 1= Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening and Grade 5 = Death. Number of participants with TEAEs by severity were reported.

    Time frame: up to Week 16

  7. Number of Participants With Clinically Significant Change From Baseline in Vital Signs

    Vital signs included body temperature, systolic and diastolic blood pressure, pulse rate, respiratory rate, weight and height. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in vital signs were reported.

    Time frame: up to Week 16

  8. Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters

    Laboratory investigation included hematology, biochemistry, urinalysis and coagulation. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in laboratory parameters were reported.

    Time frame: up to Week 16

  9. Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Findings

    12-lead ECG recordings included rhythm, heart rate (as measured by RR interval), PR interval, QRS duration, and QT interval. The corrected QT interval (QTcF) was calculated using Fridericia's formula. 12-lead ECG recordings were obtained after the participants have rested for at least 10 minutes in semisupine position. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in 12-lead ECG findings were reported.

    Time frame: up to Week 16

  10. Change From Baseline in Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 2, 4, 8, 12 and 16

    Change in the serum levels of IgG, IgA, IgM were assessed.

    Time frame: Baseline, Week 2, 4, 8, 12 and 16

  11. Change From Baseline in B Cell Count at Week 2, 4, 8, 12 and 16

    Flow cytometry analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of B cell counts.

    Time frame: Baseline, Week 2, 4, 8, 12 and 16

  12. Percentage of Participants With Remission Assessed by American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean at Week 12

    ACR-EULAR Boolean remission was when a participant satisfied all of the following: tender joint count, swollen joint count (both based on a 28-joint assessment), C-reactive Protein (in milligrams per deciliter \[mg/dL\]), and participant's global assessment (visual analog scale \[VAS\]: 0 centimeter (cm) \[very well\] to 10 cm \[worst\], higher scores indicated worse health condition) and all scores were less than or equal to (\<=) 1. Percentage of participants with ACR-EULAR Boolean Remission were reported.

    Time frame: Week 12

  13. Percentage of Participants With Clinical Disease Activity Index (CDAI) Score Less Than or Equal to [=<] 2.8 at Week 12

    CDAI: a composite index (without acute-phase reactant) for assessing disease activity. The CDAI was calculated based on following formula: CDAI = 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28) + GH + PhGA where, GH = general health component of the Disease Activity Score \[DAS\] (i.e., Participant's Global Assessment of Disease Activity, assessed using a scale of 0 to 10 centimeter (cm) Visual Analogue Scale (VAS) where 0 = very well and 10 = very poor activity and PhGA = Physician's Global Assessment of Disease Activity assessed using a scale of 0 to 10 cm VAS, where 0 = very well and 10 = very poor activity. The total CDAI score ranges from 0 to 76, where 0 (none) to 76 (extreme disease activity). CDAI score =\< 2.8 indicated clinical remission. Percentage of participants with CDAI score =\< 2.8 were reported.

    Time frame: Week 12

  14. Percentage of Participants With Simplified Disease Activity Index (SDAI) Score Less Than or Equal to [=<] 3.3 at Week 12

    SDAI was calculated based on following formula: SDAI = 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28) + GH + PGA + hsCRP where, GH = general health component of the Disease Activity Score \[DAS\] (i.e., Participant's Global Assessment of Disease Activity, assessed using a scale of 0 to 10 centimeter (cm) Visual Analogue Scale (VAS) where 0 = very well and 10 = very poor activity and PhGA = Physician's Global Assessment of Disease Activity assessed using a scale of 0 to 10 cm VAS, where 0 = very well and 10 = very poor activity. The total SDAI score ranges from 0 to 86, where 0 (none) to 86 (extreme disease activity). SDAI score =\< 3.3 indicated clinical remission. Percentage of participants with SDAI score =\< 3.3 at Week 12 were reported.

    Time frame: Week 12

  15. Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Responses at Week 12

    EULAR Responder index based on 28 joint counts categorizes clinical response based on improvement since baseline in DAS28-CRP. DAS28-CRP scores range from 0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP \>5.1, low disease activity: DAS28-CRP \<3.2, and remission: DAS28-CRP \<2.6. EULAR DAS28-CRP responder index: good (absolute: \<3.2 or \>1.2 improvement from baseline), moderate (absolute: 3.2-5.1 or 0.6-1.2 improvement from baseline), or no response (absolute: \>5.1 or \<0.6 improvement from baseline). Percentage of Participants With Good or Moderate EULAR Responses were reported.

    Time frame: Week 12

  16. American College of Rheumatology (ACR) Hybrid Scores Computed Using High-Sensitivity C-reactive Protein (hsCRP)

    The hybrid ACR combines the ACR 20/50/70 response with the mean percent change in all 7 ACR core components, thus providing a percent improvement from baseline on a continuous scale. For each participant, the mean percent improvement from baseline across the 7 ACR core set measures (tender joint count, swollen joint count, Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity, disability index of the Health Assessment Questionnaire \[HAQ\], and C-reactive protein \[CRP\]) was calculated (a positive change indicated improvement, and the maximum worst change was limited to -100%) and the ACR20, ACR50, and ACR70 response is determined. The hybrid ACR is determined from a reference table taking into account both ACR response and mean percent improvement in the core set measures. Scores can range from -100% (maximal worsening) to 100% (maximal improvement).

    Time frame: Baseline, Week 12

  17. Change From Baseline in Disease Activity Score (DAS) Based on a 28 Joint Count-High-Sensitivity C-reactive Protein (DAS28-hsCRP) at Week 12

    DAS28 was a composite score used for measuring disease activity in participants with rheumatoid arthritis. The calculation was based on the tender joint count (out of 28 joints), swollen joint count (out of 28 joints), hsCRP (milligrams per liter \[mg/L\]) and Participant's Global Assessment of Disease Activity. Total DAS28-hsCRP score ranged from 0 (none) to 9.4 (extreme disease activity). DAS28-hsCRP \< 3.2 implied low disease activity and \>= 3.2 to \<= 5.1 implied moderate disease activity, \> 5.1 implied high disease activity. DAS28-hsCRP = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(hsCRP in mg/L +1) + 0.014\* Participant's Global Assessment of Disease Activity + 0.96; ln = natural logarithm, sqrt = square root.

    Time frame: Baseline, Week 12

  18. Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 12

    The CDAI was a composite index (without acute-phase reactant) for assessing disease activity. The CDAI was calculated based on following formula: CDAI = 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28) + GH + PhGA where, GH = general health component of the DAS (i.e., Participant's Global Assessment of Disease Activity, assessed using a scale of 0 to 10 centimeter (cm) Visual Analogue Scale (VAS) where 0 = very well and 10 = very poor activity and PhGA = Physician's Global Assessment of Disease Activity assessed using a scale of 0 to 10 cm VAS, where 0 = very well and 10 = very poor activity. The total CDAI score ranges from 0 to 76, where 0 (none) to 76 (extreme disease activity).

    Time frame: Baseline, Week 12

  19. Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 12

    SDAI was numerical sum of 5 outcome parameters: 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28) + GH + PGA + hsCRP where, GH = general health component of the DAS (i.e., Participant's Global Assessment of Disease Activity, assessed using a scale of 0 to 10 centimeter (cm) Visual Analogue Scale (VAS) where 0 = very well and 10 = very poor activity and PhGA = Physician's Global Assessment of Disease Activity assessed using a scale of 0 to 10 cm VAS, where 0 = very well and 10 = very poor activity. The total SDAI score ranges from 0 to 86, where 0 (none) to 86 (extreme disease activity).

    Time frame: Baseline, Week 12

  20. Change From Baseline in Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 12

    Sixty-eight joints were assessed and classified as tender/not tender and Sixty-six joints were classified as swollen/not swollen by pressure and joint manipulation on physical examination.

    Time frame: Baseline, Week 12

  21. Change From Baseline in Participant's Global Assessment of Disease Activity Based on Visual Analog Scale (VAS) Score at Week 12

    The participant's overall assessment of disease activity was recorded using the 100 millimeter (mm) horizontal visual analog scale (VAS). The scale ranged from 0-100 mm, where 0 indicated no disease activity (symptom free and no arthritis symptoms) and 100 represented maximum disease activity (maximum arthritis disease activity).

    Time frame: Baseline, Week 12

  22. Change From Baseline in Participant's Assessment of Pain Based on Visual Analog Scale (VAS) Score at Week 12

    The participants were asked to assess their level of pain by marking a vertical tick on a 100 mm horizontal VAS scale. The scale ranged from 0-100 mm, where 0 indicated no pain and 100 indicated worst possible pain.

    Time frame: Baseline, Week 12

  23. Changes From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Total Score at Week 12

    HAQ-DI score was an evaluation of the functional status for a participant. The 20-question instrument assessed the degree of difficulty a person had in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0, indicated no difficulty, to 3, indicated inability to perform a task in that area. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range: 0-3 where 0 = least difficulty and 3 = extreme difficulty.

    Time frame: Baseline, Week 12

  24. Change From Baseline in Physician's Global Assessment of Disease Activity Scale Based on Visual Analog Scale (VAS) Score at Week 12

    The Physician's Global Assessment of Disease Activity was recorded using the 100 mm horizontal VAS. Physician rated participant's arthritis disease activity on a scale ranged from 0-100 mm, where 0 indicated no disease activity (no arthritis) and 100 represented maximum disease activity (maximum arthritis).

    Time frame: Baseline, Week 12

  25. Change From Baseline in High-Sensitivity C-reactive Protein (hsCRP) at Week 12

    hsCRP was the American College of Rheumatology (ACR) Core Set measure of acute phase reactant. It was measured at the central laboratory to help assess the effect of M2951 on the participant's rheumatoid arthritis.

    Time frame: Baseline, Week 12

  26. Percent Change From Baseline in Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 12

    Sixty-eight joints were assessed and classified as tender/not tender and Sixty-six joints were classified as swollen/not swollen by pressure and joint manipulation on physical examination.

    Time frame: Baseline, Week 12

  27. Percent Change From Baseline in Participant's Global Assessment of Disease Activity Based on Visual Analog Scale (VAS) Score at Week 12

    The participant's overall assessment of disease activity was recorded using the 100 millimeter (mm) horizontal visual analog scale (VAS). The scale ranged from 0-100 mm, where 0 indicated no disease activity (symptom free and no arthritis symptoms) and 100 represented maximum disease activity (maximum arthritis disease activity).

    Time frame: Baseline, Week 12

  28. Percent Change From Baseline in Participant's Assessment of Pain Based on Visual Analog Scale (VAS) Score at Week 12

    The participants were asked to assess their level of pain by marking a vertical tick on a 100 mm horizontal VAS scale. The scale ranged from 0-100 mm, where 0 indicated no pain and 100 indicated worst possible pain.

    Time frame: Baseline, Week 12

  29. Percent Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Total Score at Week 12

    HAQ-DI score was an evaluation of the functional status for a participant. The 20-question instrument assessed the degree of difficulty a person had in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0, indicated no difficulty, to 3, indicated inability to perform a task in that area. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range: 0-3 where 0 = least difficulty and 3 = extreme difficulty.

    Time frame: Baseline, Week 12

  30. Percent Change From Baseline in Physician's Global Assessment of Disease Activity Scale Based on Visual Analog Scale (VAS) Score at Week 12

    The Physician's Global Assessment of Disease Activity was recorded using the 100 mm horizontal VAS. Physician rated participant's arthritis disease activity on a scale ranged from 0-100 mm, where 0 indicated no disease activity (no arthritis) and 100 represented maximum disease activity (maximum arthritis).

    Time frame: Baseline, Week 12

  31. Percent Change From Baseline in High-Sensitivity C-reactive Protein (hsCRP) at Week 12

    hsCRP was the American College of Rheumatology (ACR) Core Set measure of acute phase reactant. It was measured at the central laboratory to help assess the effect of M2951 on the participant's rheumatoid arthritis.

    Time frame: Baseline, Week 12

  32. Change From Baseline in Synovitis Score According to the Outcomes Measures in Rheumatology Clinical Trials Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (OMERACT RAMRIS) at Week 12

    A total of 8 joints in the hand and wrist were evaluated for RAMRIS synovitis. Individual joint scores were assessed on a scale of 0 (no synovitis) to 3 (67 to 100 percent volume enhancement). The final synovitis score was the sum of the individual joint scores. The total score from 8 joints ranges from 0 to 24, with 0 implying normal (no synovitis) and 24 implying 67 to 100 percent volume enhancement.

    Time frame: Baseline, Week 12

  33. Change From Baseline in Bone Marrow Edema (Osteitis) Score According to the Outcomes Measures in Rheumatology Clinical Trials Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (OMERACT RAMRIS) at Week 12

    A total of 25 locations in the hand and wrist were evaluated for RAMRIS bone edema or osteitis. Individual location scores range from 0 (no edema) to 3 (67 to 100 percent involvement of original articular bone) based on the proportion of estimated originally non-eroded bone involved. The final bone edema or osteitis score is the sum of the individual location scores. The total score from the 25 locations ranges from 0 to 75, with 0 implying no bone edema or osteitis and 75 implying 67 to 100 percent involvement of original articular bone.

    Time frame: Baseline, Week 12

  34. Change From Baseline in Physical Function Using Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12

    The HAQ-DI questionnaire assessed the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.

    Time frame: Baseline, Week 12

  35. Change From Baseline in the Short-Form (SF-36) Health Survey Physical Component Score and Mental Component Score at Week 12

    The 36-Item Short-Form Health Survey (SF-36) was a standardized survey evaluating 8 aspects of functional health and well-being. These eight subscales were summarized as relating to either physical health or mental health. Physical component summary (PCS) was based primarily on physical functioning, role-physical, bodily pain, and general health scales and mental component summary (MCS) encompasses vitality, social functioning, role-emotional, and mental health scales. Score from mental health, role emotional, social functioning, and vitality domains were averaged to calculate MCS. Total score range for MCS was 0-100 (100 = highest level of mental functioning). Score from physical function, role physical, bodily pain, and general health domains were averaged to calculate PCS. Total score range for PCS was 0-100 (100 = highest level of physical functioning).

    Time frame: Baseline, Week 12

  36. Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 12

    The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assess self-reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse possible score) to 52 (best score). A higher score reflected an improvement in the participant's health status.

    Time frame: Baseline, Week 12

07

Results

Posted Sep 28, 2020

Participant flow

Participant flow — Overall Study
MilestonePlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Started97989699
Completed82838491
Not completed1515128
Withdrew: Adverse event6363
Withdrew: Protocol violation1211
Withdrew: Lack of efficacy1000
Withdrew: Other5553
Withdrew: Withdrawal by subject2201
Withdrew: Lost to follow-up0300

Outcome measures

PrimaryPercentage of Participants Who Achieved American College of Rheumatology 20 Percent (%) Response Criteria (ACR20) Assessed Using High-Sensitivity C-reactive Protein (hsCRP) at Week 12

ACR20 response: a participant has at least 20% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with 20% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by Health Assessment Questionnaire-Disability Index (HAQ-DI); and 5) acute phase reactant as measured by high-sensitivity C-reactive protein (hsCRP). Percentage of participants with ACR20 response using hsCRP = Number of participants with ACR20 response using hsCRP divided by total modified intent-to-treat (mITT) participants \* 100.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Who Achieved American College of Rheumatology 20 Percent (%) Response Criteria (ACR20) Assessed Using High-Sensitivity C-reactive Protein (hsCRP) at Week 12
percentage of participantsPlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Percentage of Participants Who Achieved American College of Rheumatology 20 Percent (%) Response Criteria (ACR20) Assessed Using High-Sensitivity C-reactive Protein (hsCRP) at Week 1249.559.251.059.6
Statistical analysis
  • Placebo vs M2951 25 mg QD · Regression, Logistic · p = 0.1746 · Odds ratio (or): 1.48 · 95% CI 0.84 to 2.61
  • Placebo vs M2951 75 mg QD · Regression, Logistic · p = 0.8283 · Odds ratio (or): 1.06 · 95% CI 0.61 to 1.87
  • Placebo vs M2951 50 mg BID · Regression, Logistic · p = 0.1298 · Odds ratio (or): 1.55 · 95% CI 0.88 to 2.74
SecondaryPercentage of Participants With Low Disease Activity Score (DAS28 Less Than [<] 3.2) Based on 28 Joint Count-High-Sensitivity C-reactive Protein (DAS28-hsCRP) at Week 12

Disease Activity Score (DAS) based on a 28 joint count hsCRP consisted of composite numerical score of following variables: tender joint count (TJC28), swollen joint count (SJC28), hsCRP (mg/mL), and participant's global assessment of disease activity. DAS28-hsCRP was calculated using following formula: DAS28-hsCRP equals to (=) 0.56\*square root (sqrt) (TJC28) plus (+) 0.28\*sqrt (SJC28) + 0.36\*natural log(hsCRP+1) + 0.014\* participant's global assessment of disease activity + 0.96. Scores ranged 0-9.4, where lower scores indicated less disease activity. Percentage of participants with low DAS28 \< 3.2 based on DAS28- hsCRP at Week 12 were reported.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Low Disease Activity Score (DAS28 Less Than [<] 3.2) Based on 28 Joint Count-High-Sensitivity C-reactive Protein (DAS28-hsCRP) at Week 12
percentage of participantsPlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Percentage of Participants With Low Disease Activity Score (DAS28 Less Than [<] 3.2) Based on 28 Joint Count-High-Sensitivity C-reactive Protein (DAS28-hsCRP) at Week 127.220.424.020.2
Statistical analysis
  • Placebo vs M2951 25 mg QD · Cochran-Mantel-Haenszel · p = 0.0077 · Response rate difference: 0.13 · 95% CI 0.04 to 0.23
  • Placebo vs M2951 75 mg QD · Cochran-Mantel-Haenszel · p = 0.0013 · Response rate difference: 0.17 · 95% CI 0.07 to 0.27
  • Placebo vs M2951 50 mg BID · Cochran-Mantel-Haenszel · p = 0.0080 · Response rate difference: 0.13 · 95% CI 0.04 to 0.23
SecondaryPercentage of Participants With Remission Disease Activity Score (DAS28 Less Than [<] 2.6) Based on a 28 Joint Count-High-Sensitivity C-reactive Protein (DAS28-hsCRP) at Week 12

Disease Activity Score (DAS) based on a 28 joint count hsCRP consisted of composite numerical score of following variables: tender joint count (TJC28), swollen joint count (SJC28), hsCRP (mg/mL), and participant's global assessment of disease activity. DAS28-hsCRP was calculated using following formula: DAS28-hsCRP equals to (=) 0.56\*square root (sqrt) (TJC28) plus (+) 0.28\*sqrt (SJC28) + 0.36\*natural log(hsCRP+1) + 0.014\* participant's global assessment of disease activity + 0.96. Scores ranged 0-9.4, where lower scores indicated less disease activity. A DAS28 score less than (\<) 2.6 indicated clinical remission. Percentage of participants with low DAS28 \< 2.6 based on DAS28- hsCRP at Week 12 were reported.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Remission Disease Activity Score (DAS28 Less Than [<] 2.6) Based on a 28 Joint Count-High-Sensitivity C-reactive Protein (DAS28-hsCRP) at Week 12
percentage of participantsPlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Percentage of Participants With Remission Disease Activity Score (DAS28 Less Than [<] 2.6) Based on a 28 Joint Count-High-Sensitivity C-reactive Protein (DAS28-hsCRP) at Week 121.010.210.410.1
Statistical analysis
  • Placebo vs M2951 25 mg QD · Cochran-Mantel-Haenszel · p = 0.0056 · Response rate difference: 0.09 · 95% CI 0.03 to 0.17
  • Placebo vs M2951 75 mg QD · Cochran-Mantel-Haenszel · p = 0.0050 · Response rate difference: 0.09 · 95% CI 0.03 to 0.17
  • Placebo vs M2951 50 mg BID · Cochran-Mantel-Haenszel · p = 0.0053 · Response rate difference: 0.09 · 95% CI 0.03 to 0.17
SecondaryPercentage of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50)

ACR50 response: a participant has at least 50% improvement in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with 50% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by Health Assessment Questionnaire - Disability Index \[HAQ-DI\]; and 5) acute phase reactant as measured by High-sensitivity C-reactive protein \[hsCRP\]. Percentage of participants with ACR50 response = Number of participants with ACR50 response divided by total mITT participants \* 100.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50)
percentage of participantsPlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Percentage of Participants Achieving American College of Rheumatology 50% Response Criteria (ACR50)19.628.627.126.3
Statistical analysis
  • Placebo vs M2951 25 mg QD · Cochran-Mantel-Haenszel · p = 0.1419 · Response rate difference: 0.09 · 95% CI -0.03 to 0.21
  • Placebo vs M2951 75 mg QD · Cochran-Mantel-Haenszel · p = 0.2202 · Response rate difference: 0.07 · 95% CI -0.05 to 0.19
  • Placebo vs M2951 50 mg BID · Cochran-Mantel-Haenszel · p = 0.2328 · Response rate difference: 0.07 · 95% CI -0.05 to 0.19
SecondaryPercentage of Participants Achieving American College of Rheumatology 70% Response Criteria (ACR70)

ACR70 response: a participant has at least 70% improvement ACR70 response in both tender joint counts (based on a total of 68 joints) and swollen joint counts (based on a total of 66 joints) together with 70% improvement in at least 3 of the following: 1) participant's assessment of pain; 2) participant's global assessment of disease activity; 3) physician's global assessment of disease activity; 4) participant's assessment of physical function measured by Health Assessment Questionnaire - Disability Index \[HAQ-DI\]; and 5) acute phase reactant as measured by High-sensitivity C-reactive protein \[hsCRP\]. Percentage of participants with ACR70 response = Number of participants with ACR70 response divided by total mITT participants \* 100.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants Achieving American College of Rheumatology 70% Response Criteria (ACR70)
percentage of participantsPlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Percentage of Participants Achieving American College of Rheumatology 70% Response Criteria (ACR70)5.211.210.410.1
Statistical analysis
  • Placebo vs M2951 25 mg QD · Cochran-Mantel-Haenszel · p = 0.1232 · Response rate difference: 0.06 · 95% CI -0.02 to 0.15
  • Placebo vs M2951 75 mg QD · Cochran-Mantel-Haenszel · p = 0.1725 · Response rate difference: 0.05 · 95% CI -0.03 to 0.14
  • Placebo vs M2951 50 mg BID · Cochran-Mantel-Haenszel · p = 0.1795 · Response rate difference: 0.05 · 95% CI -0.03 to 0.13
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)

Adverse event (AE) was defined as any untoward medical occurrence in a participant, which does not necessarily have causal relationship with treatment. A serious AE was defined as an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inparticipant hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs: events between first dose of study drug that were absent before treatment/that worsened relative to pre-treatment state up to 16 weeks. TEAEs included both serious TEAEs and non-serious TEAEs. Number of participants with TEAEs and serious TEAEs were reported.

Time frame:
up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)
ParticipantsPlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
TEAEs44484850
Serious TEAEs2221
SecondaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)

Severity of TEAEs were graded using NCI-CTCAE v4.03 toxicity grades, as follows: Grade 1= Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Life-threatening and Grade 5 = Death. Number of participants with TEAEs by severity were reported.

Time frame:
up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity According to National Cancer Institute-Common Terminology Criteria for Adverse Events Version 4.03 (NCI-CTCAE v4.03)
ParticipantsPlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Grade 133423740
Grade 219142317
Grade 32511
Grade 40100
Grade 50000
SecondaryNumber of Participants With Clinically Significant Change From Baseline in Vital Signs

Vital signs included body temperature, systolic and diastolic blood pressure, pulse rate, respiratory rate, weight and height. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in vital signs were reported.

Time frame:
up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Change From Baseline in Vital Signs
ParticipantsPlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Number of Participants With Clinically Significant Change From Baseline in Vital Signs0000
SecondaryNumber of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters

Laboratory investigation included hematology, biochemistry, urinalysis and coagulation. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in laboratory parameters were reported.

Time frame:
up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters
ParticipantsPlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Number of Participants With Clinically Significant Changes From Baseline in Laboratory Parameters0000
SecondaryNumber of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Findings

12-lead ECG recordings included rhythm, heart rate (as measured by RR interval), PR interval, QRS duration, and QT interval. The corrected QT interval (QTcF) was calculated using Fridericia's formula. 12-lead ECG recordings were obtained after the participants have rested for at least 10 minutes in semisupine position. Clinical significance was determined by the investigator. The number of participants with clinically significant changes from baseline in 12-lead ECG findings were reported.

Time frame:
up to Week 16
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Findings
ParticipantsPlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Number of Participants With Clinically Significant Changes From Baseline in 12-Lead Electrocardiogram (ECG) Findings0000
SecondaryChange From Baseline in Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 2, 4, 8, 12 and 16

Change in the serum levels of IgG, IgA, IgM were assessed.

Time frame:
Baseline, Week 2, 4, 8, 12 and 16
Reported as:
Mean · gram per liter (g/L)
Change From Baseline in Serum Immunoglobulin (Ig) Levels (IgG, IgA, IgM) at Week 2, 4, 8, 12 and 16
gram per liter (g/L)PlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
IgG: Week 2-0.02 ± 1.083-0.07 ± 1.042-0.21 ± 0.968-0.09 ± 1.062
IgG: Week 4-0.05 ± 1.465-0.15 ± 1.576-0.34 ± 1.254-0.17 ± 1.168
IgG: Week 80.12 ± 1.513-0.28 ± 2.052-0.37 ± 1.565-0.35 ± 2.037
IgG: Week 120.47 ± 1.617-0.17 ± 2.080-0.33 ± 1.493-0.23 ± 1.781
IgG: Week 160.08 ± 1.829-0.14 ± 2.349-0.14 ± 1.8080.06 ± 1.960
IgA: Week 2-0.01 ± 0.253-0.15 ± 1.1870.00 ± 0.2420.03 ± 0.369
IgA: Week 4-0.05 ± 0.326-0.01 ± 0.359-0.05 ± 0.3330.02 ± 0.396
IgA: Week 8-0.02 ± 0.346-0.16 ± 1.322-0.06 ± 0.3730.07 ± 0.567
IgA: Week 120.02 ± 0.3730.01 ± 0.444-0.08 ± 0.3880.05 ± 0.545
IgA: Week 160.01 ± 0.4660.07 ± 0.465-0.11 ± 0.3800.05 ± 0.478
IgM: Week 2-0.04 ± 0.198-0.04 ± 0.183-0.03 ± 0.281-0.01 ± 0.323
IgM: Week 4-0.04 ± 0.199-0.11 ± 0.224-0.11 ± 0.217-0.05 ± 0.385
IgM: Week 8-0.03 ± 0.310-0.20 ± 0.243-0.23 ± 0.327-0.10 ± 0.485
IgM: Week 12-0.01 ± 0.265-0.20 ± 0.309-0.25 ± 0.296-0.17 ± 0.406
IgM: Week 16-0.16 ± 0.776-0.12 ± 0.436-0.22 ± 0.246-0.12 ± 0.487
SecondaryChange From Baseline in B Cell Count at Week 2, 4, 8, 12 and 16

Flow cytometry analysis of lymphocyte populations using four-color fluorescence-activated cell sorting was performed for the analysis of B cell counts.

Time frame:
Baseline, Week 2, 4, 8, 12 and 16
Reported as:
Mean · cells per microliter (cells/microliter)
Change From Baseline in B Cell Count at Week 2, 4, 8, 12 and 16
cells per microliter (cells/microliter)PlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Week 2-13 ± 111.0264 ± 1832.7161 ± 648.374 ± 144.8
Week 4-20 ± 115.771 ± 130.166 ± 145.393 ± 137.6
Week 8-21 ± 87.535 ± 103.156 ± 188.159 ± 145.4
Week 12-22 ± 136.441 ± 111.851 ± 156.254 ± 145.0
Week 16-20 ± 121.9-3 ± 108.5-40 ± 133.5-19 ± 235.6
SecondaryPercentage of Participants With Remission Assessed by American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean at Week 12

ACR-EULAR Boolean remission was when a participant satisfied all of the following: tender joint count, swollen joint count (both based on a 28-joint assessment), C-reactive Protein (in milligrams per deciliter \[mg/dL\]), and participant's global assessment (visual analog scale \[VAS\]: 0 centimeter (cm) \[very well\] to 10 cm \[worst\], higher scores indicated worse health condition) and all scores were less than or equal to (\<=) 1. Percentage of participants with ACR-EULAR Boolean Remission were reported.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Remission Assessed by American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean at Week 12
percentage of participantsPlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Percentage of Participants With Remission Assessed by American College of Rheumatology-European League Against Rheumatism (ACR-EULAR) Boolean at Week 120.00.01.03.0
Statistical analysis
  • Placebo vs M2951 25 mg QD · Response rate difference: 0.00 · 95% CI -0.04 to 0.04
  • Placebo vs M2951 75 mg QD · Response rate difference: 0.01 · 95% CI -0.03 to 0.06
  • Placebo vs M2951 50 mg BID · Response rate difference: 0.03 · 95% CI -0.01 to 0.09
SecondaryPercentage of Participants With Clinical Disease Activity Index (CDAI) Score Less Than or Equal to [=<] 2.8 at Week 12

CDAI: a composite index (without acute-phase reactant) for assessing disease activity. The CDAI was calculated based on following formula: CDAI = 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28) + GH + PhGA where, GH = general health component of the Disease Activity Score \[DAS\] (i.e., Participant's Global Assessment of Disease Activity, assessed using a scale of 0 to 10 centimeter (cm) Visual Analogue Scale (VAS) where 0 = very well and 10 = very poor activity and PhGA = Physician's Global Assessment of Disease Activity assessed using a scale of 0 to 10 cm VAS, where 0 = very well and 10 = very poor activity. The total CDAI score ranges from 0 to 76, where 0 (none) to 76 (extreme disease activity). CDAI score =\< 2.8 indicated clinical remission. Percentage of participants with CDAI score =\< 2.8 were reported.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Clinical Disease Activity Index (CDAI) Score Less Than or Equal to [=<] 2.8 at Week 12
percentage of participantsPlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Percentage of Participants With Clinical Disease Activity Index (CDAI) Score Less Than or Equal to [=<] 2.8 at Week 121.04.16.33.0
Statistical analysis
  • Placebo vs M2951 25 mg QD · Response rate difference: 0.03 · 95% CI -0.02 to 0.09
  • Placebo vs M2951 75 mg QD · Response rate difference: 0.05 · 95% CI -0.00 to 0.12
  • Placebo vs M2951 50 mg BID · Response rate difference: 0.02 · 95% CI -0.03 to 0.08
SecondaryPercentage of Participants With Simplified Disease Activity Index (SDAI) Score Less Than or Equal to [=<] 3.3 at Week 12

SDAI was calculated based on following formula: SDAI = 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28) + GH + PGA + hsCRP where, GH = general health component of the Disease Activity Score \[DAS\] (i.e., Participant's Global Assessment of Disease Activity, assessed using a scale of 0 to 10 centimeter (cm) Visual Analogue Scale (VAS) where 0 = very well and 10 = very poor activity and PhGA = Physician's Global Assessment of Disease Activity assessed using a scale of 0 to 10 cm VAS, where 0 = very well and 10 = very poor activity. The total SDAI score ranges from 0 to 86, where 0 (none) to 86 (extreme disease activity). SDAI score =\< 3.3 indicated clinical remission. Percentage of participants with SDAI score =\< 3.3 at Week 12 were reported.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Simplified Disease Activity Index (SDAI) Score Less Than or Equal to [=<] 3.3 at Week 12
percentage of participantsPlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Percentage of Participants With Simplified Disease Activity Index (SDAI) Score Less Than or Equal to [=<] 3.3 at Week 120.03.14.23.0
Statistical analysis
  • Placebo vs M2951 25 mg QD · Response rate difference: 0.03 · 95% CI -0.01 to 0.09
  • Placebo vs M2951 75 mg QD · Response rate difference: 0.04 · 95% CI 0.00 to 0.10
  • Placebo vs M2951 50 mg BID · Response rate difference: 0.03 · 95% CI -0.01 to 0.09
SecondaryPercentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Responses at Week 12

EULAR Responder index based on 28 joint counts categorizes clinical response based on improvement since baseline in DAS28-CRP. DAS28-CRP scores range from 0-9.4, where lower scores indicated less disease activity. High disease activity: DAS28-CRP \>5.1, low disease activity: DAS28-CRP \<3.2, and remission: DAS28-CRP \<2.6. EULAR DAS28-CRP responder index: good (absolute: \<3.2 or \>1.2 improvement from baseline), moderate (absolute: 3.2-5.1 or 0.6-1.2 improvement from baseline), or no response (absolute: \>5.1 or \<0.6 improvement from baseline). Percentage of Participants With Good or Moderate EULAR Responses were reported.

Time frame:
Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Responses at Week 12
percentage of participantsPlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Percentage of Participants With Good or Moderate European League Against Rheumatism (EULAR) Responses at Week 1254.665.366.771.7
Statistical analysis
  • Placebo vs M2951 25 mg QD · Response rate difference: 0.11 · 95% CI -0.03 to 0.24
  • Placebo vs M2951 75 mg QD · Response rate difference: 0.12 · 95% CI -0.02 to 0.25
  • Placebo vs M2951 50 mg BID · Response rate difference: 0.18 · 95% CI 0.05 to 0.31
SecondaryAmerican College of Rheumatology (ACR) Hybrid Scores Computed Using High-Sensitivity C-reactive Protein (hsCRP)

The hybrid ACR combines the ACR 20/50/70 response with the mean percent change in all 7 ACR core components, thus providing a percent improvement from baseline on a continuous scale. For each participant, the mean percent improvement from baseline across the 7 ACR core set measures (tender joint count, swollen joint count, Patient's Global Assessment of Disease Activity, Physician's Global Assessment of Disease Activity, disability index of the Health Assessment Questionnaire \[HAQ\], and C-reactive protein \[CRP\]) was calculated (a positive change indicated improvement, and the maximum worst change was limited to -100%) and the ACR20, ACR50, and ACR70 response is determined. The hybrid ACR is determined from a reference table taking into account both ACR response and mean percent improvement in the core set measures. Scores can range from -100% (maximal worsening) to 100% (maximal improvement).

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change
American College of Rheumatology (ACR) Hybrid Scores Computed Using High-Sensitivity C-reactive Protein (hsCRP)
percent changePlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
American College of Rheumatology (ACR) Hybrid Scores Computed Using High-Sensitivity C-reactive Protein (hsCRP)26.51 ± 25.77934.66 ± 29.03333.09 ± 27.72436.99 ± 26.241
SecondaryChange From Baseline in Disease Activity Score (DAS) Based on a 28 Joint Count-High-Sensitivity C-reactive Protein (DAS28-hsCRP) at Week 12

DAS28 was a composite score used for measuring disease activity in participants with rheumatoid arthritis. The calculation was based on the tender joint count (out of 28 joints), swollen joint count (out of 28 joints), hsCRP (milligrams per liter \[mg/L\]) and Participant's Global Assessment of Disease Activity. Total DAS28-hsCRP score ranged from 0 (none) to 9.4 (extreme disease activity). DAS28-hsCRP \< 3.2 implied low disease activity and \>= 3.2 to \<= 5.1 implied moderate disease activity, \> 5.1 implied high disease activity. DAS28-hsCRP = 0.56\*sqrt(TJC28) + 0.28\*sqrt(SJC28) + 0.36\*ln(hsCRP in mg/L +1) + 0.014\* Participant's Global Assessment of Disease Activity + 0.96; ln = natural logarithm, sqrt = square root.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Disease Activity Score (DAS) Based on a 28 Joint Count-High-Sensitivity C-reactive Protein (DAS28-hsCRP) at Week 12
units on a scalePlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Change From Baseline in Disease Activity Score (DAS) Based on a 28 Joint Count-High-Sensitivity C-reactive Protein (DAS28-hsCRP) at Week 12-1.21 ± 1.048-1.45 ± 1.230-1.62 ± 1.257-1.75 ± 1.229
SecondaryChange From Baseline in Clinical Disease Activity Index (CDAI) at Week 12

The CDAI was a composite index (without acute-phase reactant) for assessing disease activity. The CDAI was calculated based on following formula: CDAI = 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28) + GH + PhGA where, GH = general health component of the DAS (i.e., Participant's Global Assessment of Disease Activity, assessed using a scale of 0 to 10 centimeter (cm) Visual Analogue Scale (VAS) where 0 = very well and 10 = very poor activity and PhGA = Physician's Global Assessment of Disease Activity assessed using a scale of 0 to 10 cm VAS, where 0 = very well and 10 = very poor activity. The total CDAI score ranges from 0 to 76, where 0 (none) to 76 (extreme disease activity).

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 12
units on a scalePlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Change From Baseline in Clinical Disease Activity Index (CDAI) at Week 12-16.9 ± 13.09-18.0 ± 13.00-18.9 ± 14.33-20.3 ± 13.90
SecondaryChange From Baseline in Simplified Disease Activity Index (SDAI) at Week 12

SDAI was numerical sum of 5 outcome parameters: 28 joint count for swelling (SJC28) + 28 joint count for tenderness (TJC28) + GH + PGA + hsCRP where, GH = general health component of the DAS (i.e., Participant's Global Assessment of Disease Activity, assessed using a scale of 0 to 10 centimeter (cm) Visual Analogue Scale (VAS) where 0 = very well and 10 = very poor activity and PhGA = Physician's Global Assessment of Disease Activity assessed using a scale of 0 to 10 cm VAS, where 0 = very well and 10 = very poor activity. The total SDAI score ranges from 0 to 86, where 0 (none) to 86 (extreme disease activity).

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 12
units on a scalePlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Change From Baseline in Simplified Disease Activity Index (SDAI) at Week 12-17.000 ± 13.5175-18.647 ± 13.5957-19.404 ± 14.1591-21.053 ± 14.3720
SecondaryChange From Baseline in Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 12

Sixty-eight joints were assessed and classified as tender/not tender and Sixty-six joints were classified as swollen/not swollen by pressure and joint manipulation on physical examination.

Time frame:
Baseline, Week 12
Reported as:
Mean · joints
Change From Baseline in Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 12
jointsPlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
TJC-11 ± 12.0-11 ± 10.6-13 ± 13.2-12 ± 10.8
SJC-7 ± 7.5-8 ± 6.1-8 ± 7.7-8 ± 6.6
SecondaryChange From Baseline in Participant's Global Assessment of Disease Activity Based on Visual Analog Scale (VAS) Score at Week 12

The participant's overall assessment of disease activity was recorded using the 100 millimeter (mm) horizontal visual analog scale (VAS). The scale ranged from 0-100 mm, where 0 indicated no disease activity (symptom free and no arthritis symptoms) and 100 represented maximum disease activity (maximum arthritis disease activity).

Time frame:
Baseline, Week 12
Reported as:
Mean · millimeter (mm)
Change From Baseline in Participant's Global Assessment of Disease Activity Based on Visual Analog Scale (VAS) Score at Week 12
millimeter (mm)PlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Change From Baseline in Participant's Global Assessment of Disease Activity Based on Visual Analog Scale (VAS) Score at Week 12-20 ± 29.6-19 ± 27.9-17 ± 29.6-25 ± 25.7
SecondaryChange From Baseline in Participant's Assessment of Pain Based on Visual Analog Scale (VAS) Score at Week 12

The participants were asked to assess their level of pain by marking a vertical tick on a 100 mm horizontal VAS scale. The scale ranged from 0-100 mm, where 0 indicated no pain and 100 indicated worst possible pain.

Time frame:
Baseline, Week 12
Reported as:
Mean · millimeter
Change From Baseline in Participant's Assessment of Pain Based on Visual Analog Scale (VAS) Score at Week 12
millimeterPlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Change From Baseline in Participant's Assessment of Pain Based on Visual Analog Scale (VAS) Score at Week 12-21 ± 24.7-24 ± 26.9-22 ± 24.7-25 ± 26.6
SecondaryChanges From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Total Score at Week 12

HAQ-DI score was an evaluation of the functional status for a participant. The 20-question instrument assessed the degree of difficulty a person had in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0, indicated no difficulty, to 3, indicated inability to perform a task in that area. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range: 0-3 where 0 = least difficulty and 3 = extreme difficulty.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Changes From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Total Score at Week 12
units on a scalePlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Changes From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Total Score at Week 12-0.38 ± 0.567-0.58 ± 0.662-0.40 ± 0.658-0.52 ± 0.616
SecondaryChange From Baseline in Physician's Global Assessment of Disease Activity Scale Based on Visual Analog Scale (VAS) Score at Week 12

The Physician's Global Assessment of Disease Activity was recorded using the 100 mm horizontal VAS. Physician rated participant's arthritis disease activity on a scale ranged from 0-100 mm, where 0 indicated no disease activity (no arthritis) and 100 represented maximum disease activity (maximum arthritis).

Time frame:
Baseline, Week 12
Reported as:
Mean · millimeter
Change From Baseline in Physician's Global Assessment of Disease Activity Scale Based on Visual Analog Scale (VAS) Score at Week 12
millimeterPlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Change From Baseline in Physician's Global Assessment of Disease Activity Scale Based on Visual Analog Scale (VAS) Score at Week 12-29 ± 21.2-33 ± 26.5-34 ± 26.1-37 ± 25.3
SecondaryChange From Baseline in High-Sensitivity C-reactive Protein (hsCRP) at Week 12

hsCRP was the American College of Rheumatology (ACR) Core Set measure of acute phase reactant. It was measured at the central laboratory to help assess the effect of M2951 on the participant's rheumatoid arthritis.

Time frame:
Baseline, Week 12
Reported as:
Mean · milligram per liter (mg/L)
Change From Baseline in High-Sensitivity C-reactive Protein (hsCRP) at Week 12
milligram per liter (mg/L)PlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Change From Baseline in High-Sensitivity C-reactive Protein (hsCRP) at Week 12-1.11 ± 25.925-6.42 ± 23.280-5.45 ± 28.807-7.69 ± 23.007
SecondaryPercent Change From Baseline in Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 12

Sixty-eight joints were assessed and classified as tender/not tender and Sixty-six joints were classified as swollen/not swollen by pressure and joint manipulation on physical examination.

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Tender Joint Count (TJC) and Swollen Joint Count (SJC) at Week 12
percent changePlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
TJC-39 ± 45.6-46 ± 44.2-51 ± 42.8-49 ± 37.5
SJC-46 ± 52.7-53 ± 42.6-56 ± 40.3-58 ± 43.8
SecondaryPercent Change From Baseline in Participant's Global Assessment of Disease Activity Based on Visual Analog Scale (VAS) Score at Week 12

The participant's overall assessment of disease activity was recorded using the 100 millimeter (mm) horizontal visual analog scale (VAS). The scale ranged from 0-100 mm, where 0 indicated no disease activity (symptom free and no arthritis symptoms) and 100 represented maximum disease activity (maximum arthritis disease activity).

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Participant's Global Assessment of Disease Activity Based on Visual Analog Scale (VAS) Score at Week 12
percent changePlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Percent Change From Baseline in Participant's Global Assessment of Disease Activity Based on Visual Analog Scale (VAS) Score at Week 12-13 ± 111.0-21 ± 69.3-13 ± 65.7-33 ± 35.9
SecondaryPercent Change From Baseline in Participant's Assessment of Pain Based on Visual Analog Scale (VAS) Score at Week 12

The participants were asked to assess their level of pain by marking a vertical tick on a 100 mm horizontal VAS scale. The scale ranged from 0-100 mm, where 0 indicated no pain and 100 indicated worst possible pain.

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Participant's Assessment of Pain Based on Visual Analog Scale (VAS) Score at Week 12
percent changePlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Percent Change From Baseline in Participant's Assessment of Pain Based on Visual Analog Scale (VAS) Score at Week 12-23 ± 65.0-32 ± 38.4-29 ± 40.5-32 ± 48.4
SecondaryPercent Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Total Score at Week 12

HAQ-DI score was an evaluation of the functional status for a participant. The 20-question instrument assessed the degree of difficulty a person had in accomplishing tasks in 8 functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping, and activities of daily living). Responses in each functional area were scored from 0, indicated no difficulty, to 3, indicated inability to perform a task in that area. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range: 0-3 where 0 = least difficulty and 3 = extreme difficulty.

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Total Score at Week 12
percent changePlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Percent Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) Total Score at Week 12-20.09 ± 40.084-31.85 ± 37.124-21.27 ± 44.571-27.12 ± 42.624
SecondaryPercent Change From Baseline in Physician's Global Assessment of Disease Activity Scale Based on Visual Analog Scale (VAS) Score at Week 12

The Physician's Global Assessment of Disease Activity was recorded using the 100 mm horizontal VAS. Physician rated participant's arthritis disease activity on a scale ranged from 0-100 mm, where 0 indicated no disease activity (no arthritis) and 100 represented maximum disease activity (maximum arthritis).

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in Physician's Global Assessment of Disease Activity Scale Based on Visual Analog Scale (VAS) Score at Week 12
percent changePlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Percent Change From Baseline in Physician's Global Assessment of Disease Activity Scale Based on Visual Analog Scale (VAS) Score at Week 12-42 ± 31.4-44 ± 51.9-47 ± 34.9-52 ± 33.5
SecondaryPercent Change From Baseline in High-Sensitivity C-reactive Protein (hsCRP) at Week 12

hsCRP was the American College of Rheumatology (ACR) Core Set measure of acute phase reactant. It was measured at the central laboratory to help assess the effect of M2951 on the participant's rheumatoid arthritis.

Time frame:
Baseline, Week 12
Reported as:
Mean · percent change
Percent Change From Baseline in High-Sensitivity C-reactive Protein (hsCRP) at Week 12
percent changePlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Percent Change From Baseline in High-Sensitivity C-reactive Protein (hsCRP) at Week 1295.01 ± 380.16110.93 ± 167.257182.57 ± 1775.154-13.91 ± 105.688
SecondaryChange From Baseline in Synovitis Score According to the Outcomes Measures in Rheumatology Clinical Trials Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (OMERACT RAMRIS) at Week 12

A total of 8 joints in the hand and wrist were evaluated for RAMRIS synovitis. Individual joint scores were assessed on a scale of 0 (no synovitis) to 3 (67 to 100 percent volume enhancement). The final synovitis score was the sum of the individual joint scores. The total score from 8 joints ranges from 0 to 24, with 0 implying normal (no synovitis) and 24 implying 67 to 100 percent volume enhancement.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Synovitis Score According to the Outcomes Measures in Rheumatology Clinical Trials Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (OMERACT RAMRIS) at Week 12
units on a scalePlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Change From Baseline in Synovitis Score According to the Outcomes Measures in Rheumatology Clinical Trials Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (OMERACT RAMRIS) at Week 120 ± 1.9-1 ± 2.5-1 ± 3.4-1 ± 2.4
SecondaryChange From Baseline in Bone Marrow Edema (Osteitis) Score According to the Outcomes Measures in Rheumatology Clinical Trials Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (OMERACT RAMRIS) at Week 12

A total of 25 locations in the hand and wrist were evaluated for RAMRIS bone edema or osteitis. Individual location scores range from 0 (no edema) to 3 (67 to 100 percent involvement of original articular bone) based on the proportion of estimated originally non-eroded bone involved. The final bone edema or osteitis score is the sum of the individual location scores. The total score from the 25 locations ranges from 0 to 75, with 0 implying no bone edema or osteitis and 75 implying 67 to 100 percent involvement of original articular bone.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Bone Marrow Edema (Osteitis) Score According to the Outcomes Measures in Rheumatology Clinical Trials Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (OMERACT RAMRIS) at Week 12
units on a scalePlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Change From Baseline in Bone Marrow Edema (Osteitis) Score According to the Outcomes Measures in Rheumatology Clinical Trials Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (OMERACT RAMRIS) at Week 12-1 ± 5.80 ± 4.60 ± 5.40 ± 4.0
SecondaryChange From Baseline in Physical Function Using Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12

The HAQ-DI questionnaire assessed the participant's self-perception on the degree of difficulty \[0 (without any difficulty), 1 (with some difficulty), 2 (with much difficulty), and 3 (unable to do)\] when dressing and grooming, arising, eating, walking, hygiene, reaching, gripping, and performing other daily activities. Scores for each functional area were averaged to calculate HAQ-DI scores, which ranged from 0 (no disability) to 3 (worst disability). A decrease in HAQ-DI score indicated an improvement in the participant's condition.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Physical Function Using Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12
units on a scalePlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Change From Baseline in Physical Function Using Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12-0.41 ± 0.543-0.61 ± 0.637-0.45 ± 0.657-0.53 ± 0.631
SecondaryChange From Baseline in the Short-Form (SF-36) Health Survey Physical Component Score and Mental Component Score at Week 12

The 36-Item Short-Form Health Survey (SF-36) was a standardized survey evaluating 8 aspects of functional health and well-being. These eight subscales were summarized as relating to either physical health or mental health. Physical component summary (PCS) was based primarily on physical functioning, role-physical, bodily pain, and general health scales and mental component summary (MCS) encompasses vitality, social functioning, role-emotional, and mental health scales. Score from mental health, role emotional, social functioning, and vitality domains were averaged to calculate MCS. Total score range for MCS was 0-100 (100 = highest level of mental functioning). Score from physical function, role physical, bodily pain, and general health domains were averaged to calculate PCS. Total score range for PCS was 0-100 (100 = highest level of physical functioning).

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in the Short-Form (SF-36) Health Survey Physical Component Score and Mental Component Score at Week 12
units on a scalePlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
PCS5.9 ± 7.107.1 ± 8.506.4 ± 8.507.1 ± 8.28
MCS4.9 ± 11.465.7 ± 8.415.0 ± 11.724.7 ± 8.95
SecondaryChange From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 12

The FACIT-Fatigue score was calculated according to a 13-item questionnaire that assess self-reported fatigue and its impact upon daily activities and function. It uses a 5-point Likert-type scale (0 = not at all; 1 = a little bit; 2 = somewhat; 3 = quite a bit; 4 = very much). The sum of all responses resulted in the FACIT-Fatigue score for a total possible score of 0 (worse possible score) to 52 (best score). A higher score reflected an improvement in the participant's health status.

Time frame:
Baseline, Week 12
Reported as:
Mean · units on a scale
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 12
units on a scalePlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
Change From Baseline in Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue Score at Week 129 ± 11.410 ± 9.49 ± 9.08 ± 10.7

Adverse events

Collected over up to Week 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo0/97 (0%)2/97 (2.1%)11/97 (11.3%)
M2951 25 mg QD0/98 (0%)2/98 (2%)13/98 (13.3%)
M2951 75 mg QD0/96 (0%)2/96 (2.1%)8/96 (8.3%)
M2951 50 mg BID0/99 (0%)1/99 (1%)17/99 (17.2%)
Most frequent serious events
Most frequent serious events
EventPlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
OsteomyelitisInfections and infestations0/970/981/960/99
Tibia fractureInjury, poisoning and procedural complications0/970/981/960/99
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders1/970/980/960/99
Thrombophlebitis superficialVascular disorders1/970/980/960/99
HypersensitivityImmune system disorders0/971/980/960/99
SinusitisInfections and infestations0/971/980/960/99
LymphoedemaVascular disorders0/971/980/960/99
HepatotoxicityHepatobiliary disorders0/970/980/961/99
Most frequent other events
Most frequent other events
EventPlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BID
HeadacheNervous system disorders5/976/985/968/99
AnaemiaBlood and lymphatic system disorders6/972/983/967/99
DyslipidaemiaMetabolism and nutrition disorders0/975/980/962/99

Baseline characteristics

The modified intent-to-treat (mITT) analysis set included all randomized participants who received at least one dose of Investigational Medicinal Product (IMP) (M2951 or placebo).

Age, Continuous
Age, Continuous(years)PlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BIDTotal
Mean52.9 ± 12.2450.9 ± 13.1553.3 ± 11.3353.7 ± 12.1352.7 ± 12.21
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BIDTotal
Female77827677312
Male2016202278
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BIDTotal
Hispanic or Latino32333538138
Not Hispanic or Latino65656161252
Unknown or Not Reported00000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboM2951 25 mg QDM2951 75 mg QDM2951 50 mg BIDTotal
American Indian or Alaska Native00000
Asian11103
Native Hawaiian or Other Pacific Islander00000
Black or African American12003
White92949197374
More than one race00000
Unknown or Not Reported314210
08

Study locations

98 sites
  • Arizona Arthritis & Rheumatology Associates, P.C.
    Phoenix, Arizona 85032, United States
  • Arizona Arthritis & Rheumatology Research, PLLC
    Phoenix, Arizona 85037, United States
  • East Bay Rheumatology Medical Group, Inc.
    San Leandro, California 94578, United States
  • Omega Research Consultants
    DeBary, Florida 32713, United States
  • Clinical Research of West Florida, Inc.
    Tampa, Florida 33603, United States
  • McIlwain Medical Group, PA
    Tampa, Florida 33614, United States
  • Medication Management, LLC
    Greensboro, North Carolina 27410, United States
  • Arthritis Clinic Of Central Texas
    San Marcos, Texas 78666, United States
  • Hospital Italiano de La Plata
    La Plata, Buenos Aires B1900AXI, Argentina
  • Instituto de Investigaciones Clinicas
    Mar del Plata, Buenos Aires B7600FZ, Argentina
  • Instituto Medico CER
    Quilmes, Buenos Aires B1878DVB, Argentina
  • Instituto de Investigaciones Clinicas Quilmes
    Quilmes, Buenos Aires B1878GEG, Argentina
  • Centro Medico Privado de Reumatologia
    Tucuman, San Miguel De Tucuman T4000AXL, Argentina
  • Centro de Investigaciones Reumatológicas
    San Miguel de Tucuman, Tucuman T4000BRD, Argentina
  • Organizacion Medica de Investigacion (OMI)
    Ciudad Autonoma Buenos Aires, C1015ABO, Argentina
  • APRILLUS
    Ciudad Autonoma Buenos Aires, C1046AAQ, Argentina
  • Expertia S.A- Mautalen Salud e Investigación
    Ciudad Autonoma Buenos Aires, C1128AAE, Argentina
  • Hospital General de Agudos Dr. J. M. Ramos Mejia
    Ciudad Autonoma Buenos Aires, C1221ADC, Argentina
  • ILAIM-CEOM Inst. Latinoamericano de Inv. Medicas
    Cordoba, X5000BNB, Argentina
  • Instituto Reumatológico Strusberg
    Cordoba, X5000EDC, Argentina
  • Centro Polivalente de Asistencia e Inv. Clinica CER
    San Juan, 5400, Argentina
  • MHAT "Hadzhi Dimitar", OOD
    Sliven, 8800, Bulgaria
  • DCC "Alexandrovska", EOOD
    Sofia, 1431, Bulgaria
  • UMHAT "SofiaMed", OOD
    Sofia, 1797, Bulgaria
  • Centro Medico Prosalud
    Santiago, 7500000, Chile
  • Interin
    Santiago, 7500010, Chile
  • BioMedica Research Group
    Santiago, 7500710, Chile
  • Centro de Estudios Reumatologicos
    Santiago, 7501126, Chile
  • Centro de Reumatologia y Ortopedia SAS
    Barranquilla, 080001, Colombia
  • Riesgo de Fractura S.A.
    Bogota, 110221, Colombia
  • Simedics Ips Sas
    Bogotá, 111211, Colombia
  • Centro de Investigacion en Reumatologia y Especialidades Medicas SAS. CIREEM
    Bogotá, Colombia
  • Servimed S.A.S.
    Bucaramanga, 680003, Colombia
  • Clinica de Artritis Temprana S.A.
    Cali, 76001, Colombia
  • Revmatolog, s.r.o
    Jihlava, 586 01, Czechia
  • ARTROSCAN s.r.o.
    Ostrava - Trebovice, 722 00, Czechia
  • CCBR Ostrava s.r.o.
    Ostrava, 702 00, Czechia
  • CLINTRIAL s.r.o.
    Praha 10, 100 00, Czechia
  • Thomayerova nemocnice
    Praha 4 - Krc, 140 59, Czechia
  • MUDR. Zuzana URBANOVA Revmatologie
    Praha 4 Nusle, 140 00, Czechia
  • MUDR. Zuzana URBANOVA Revmatologie
    Praha 4, 140 00, Czechia
  • MEDICAL PLUS s.r.o.
    Uherske Hradiste, 686 01, Czechia
  • PV-MEDICAL s.r.o.
    Zlin, 760 01, Czechia
  • Centro Investigacion en Artritis y Osteoporosis S.C.
    Mexicali, Baja California Norte 21200, Mexico
  • RM Pharma Specialists SA de CV
    Mexico, Distrito Federal 03100, Mexico
  • Clinica de Investigacion en Reumatologia y Obesidad S.C.
    Guadalajara, Jalisco 44650, Mexico
  • Investigacion y Biomedicina de Chihuahua, S.C.
    Chihuahua, 31000, Mexico
  • Centro de Investigacion y Atencion Integral Durango CIAID
    Durango, 34270, Mexico
  • ClinicMed Daniluk, Nowak Spółka Jawna
    Bialystok, 15-879, Poland
  • Centrum Reumatologiczne Indywidualna Specjalistyczna Praktyka Lekarska lek. Barbara Bazela
    Elblag, 82-300, Poland
  • MCBK Iwona Czajkowska Anna Podrażka- Szczepaniak S.C.
    Grodzisk Mazowiecki, 05-825, Poland
  • Care Clinic
    Katowice, 40-060, Poland
  • Silmedic sp. z o.o
    Katowice, 40-282, Poland
  • GLOBE CLINICAL RESEARCH (Globe Badania Kliniczne Sp z o.o.)
    Klodzko, 57-300, Poland
  • Indywidualna Specjalistyczna Praktyka Lekarska Maciej Zymla
    Knurow, 44-190, Poland
  • Malopolskie Centrum Medyczne s.c.
    Krakow, 30-510, Poland
  • Grazyna Pulka Specjalistyczny Osrodek "ALL-MED"
    Krakow, 31-024, Poland
  • Centrum Badan Klinicznych S.C.
    Poznan, 60-773, Poland
  • RCMed
    Sochaczew, 96-500, Poland
  • Centrum Medyczne AMED
    Warsaw, 03-291, Poland
  • Medycyna Kliniczna
    Warszawa, 00-660, Poland
  • Rheuma Medicus Zaklad Opieki Zdrowotnej
    Warszawa, 02-118, Poland
  • Wojskowy Instytut Medyczny
    Warszawa, 04-141, Poland
  • Reum-Medica S.C Eliza Roszkowska
    Wroclaw, 50-244, Poland
  • Research Institute of Emergency Medical Care
    St. Petersburg, Saint Petersburg 192242, Russian Federation
  • Limited Liability Company "Centre of Medical Common Practice"
    Novosibirsk, 630091, Russian Federation
  • Ultramed
    Omsk, 644024, Russian Federation
  • SPb SBIH "Clinical Rheumatological Hospital # 25"
    Saint-Petersburg, 190068, Russian Federation
  • LLC Medical Sanitary Unit#157
    Saint-Petersburg, 196066, Russian Federation
  • NIH "Departmental Hospital on Station Smolensk of OJSC "Russian Railways"
    Smolensk, 214025, Russian Federation
  • SAIH of Yaroslavl region "Clinical Hospital of Emergency Medical Care n.a. N. V. Solovyev"
    Yaroslavl, 150003, Russian Federation
  • SBHI of Yaroslavl Region "Clinical Hospital # 8"
    Yaroslavl, 150003, Russian Federation
  • Institute of Rheumatology_Site 1
    Belgrade, 11000, Serbia
  • Military Medical Academy
    Belgrade, 11000, Serbia
  • Clinical Center Bezanijska kosa
    Belgrade, 11080, Serbia
  • Institute of Treatment and Rehabilitation "Niska Banja"
    Niska Banja, 18205, Serbia
  • General Hospital "Dr Laza K. Lazarevic" Sabac
    Sabac, 15000, Serbia
  • Wits Clinical Research
    Johannesburg, Gauteng 2193, South Africa
  • Clinresco Centres (Pty) Ltd
    Kempton Park, Gauteng 1619, South Africa
  • Emmed Research
    Pretoria, Gauteng 0002, South Africa
  • University of Pretoria Clinical Research Unit
    Pretoria, Gauteng 0002, South Africa
  • Naidoo, A
    Durban, KwaZulu-Natal 4319, South Africa
  • Arthritis Clinical Research Trial Unit
    Cape Town, Western Cape 7405, South Africa
  • Winelands Medical Research Centre
    Stellenbosch, Western Cape 7600, South Africa
  • Regional CH Dep of Rheumatology SHEI Ivano-Frankivsk NMU
    Ivano-Frankivsk, 76008, Ukraine
  • GI L.T.Malaya Therapy National Institute of the NAMS of Ukraine
    Kharkiv, 61039, Ukraine
  • Communal Institution of Healthcare Kharkiv City Clinical Hospital #8
    Kharkiv, 61176, Ukraine
  • Medical Center Medical Clinic Blagomed LLC
    Kyiv, 01601, Ukraine
  • Med Center 'Ok!Clinic+' of International Institute of Clinical Trials LLC
    Kyiv, 02091, Ukraine
  • Medical Center of Revmotsentr LLC
    Kyiv, 04070, Ukraine
  • SI D.F.Chebotariov Institute of Gerontology of NAMSU
    Kyiv, 04114, Ukraine
  • CH of State Border Service of Ukraine (Military Base 2522) Dept of Therapy, D.Halytskyi Lviv NMU
    Lviv, 79049, Ukraine
  • M.V. Sklifosovskyi Poltava RCH Dept of Rheumatology HSEIU UMSA
    Poltava, 36011, Ukraine
  • A.Novak Transcarpathian Regional Clinical Hospital
    Uzhgorod, 88000, Ukraine
  • National Pirogov Memorial Medical University
    Vinnytsia, 21018, Ukraine
  • CI City Hospital #1
    Zaporizhzhia, 69104, Ukraine
  • CI Zaporizhzhia Regional Clinical Hospital of ZRC
    Zaporizhzhia, 69600, Ukraine
  • CI Zaporizhzhia Regional Clinical Hospital of ZRC
    Zaporizhzhya, 69600, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Per company policy, following approval of a new product or a new indication for an approved product in both the EU and the US, EMD Serono will share study protocols, anonymized patient level and study level data and redacted clinical study reports from clinical trials in patients with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website https://www.emdgroup.com/en/research/our-approach-to-research-and-development/healthcare/clinical-trials/commitment-responsible-data-sharing.html

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2017 to primary completion in Sep 2019, 24 months.

Results were first posted in Sep 2020, 1 year after primary completion.

Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 24 months is above that.

Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 25, 2017
First posted
Jul 28, 2017
StartActual
Sep 18, 2017
Primary completionActual
Sep 23, 2019
CompletionActual
Sep 23, 2019
Results first posted
Sep 28, 2020
Last update
Sep 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03233230
Responsible party
Sponsor
First posted
Jul 28, 2017
Start date
Sep 18, 2017
Primary completion
Sep 23, 2019
Completion
Sep 23, 2019
Results posted
Sep 28, 2020
Last update
Sep 28, 2020

Study contacts

Medical Responsible
study director · EMD Serono Research & Development Institute, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Evobrutinib

Start the discussion